Does the media prefer LFVN or EDIT?

In the previous week, Lifevantage and Lifevantage both had 1 articles in the media. Editas Medicine's average media sentiment score of 1.16 beat Lifevantage's score of 1.05 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifevantage 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, LFVN or IRD?

Lifevantage has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifevantage $228.53M 0.35 $9.81M $0.45 13.91 Opus Genetics $14.20M 17.74 -$49.59M -$1.33 N/A

Is LFVN or IRD more profitable?

Lifevantage has a net margin of 2.94% compared to Opus Genetics' net margin of -892.36%. Lifevantage's return on equity of 23.89% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Lifevantage 2.94% 23.89% 12.47% Opus Genetics -892.36% -338.88% -191.21%

Does the media favor LFVN or IRD?

In the previous week, Opus Genetics had 2 more articles in the media than Lifevantage. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.05 beat Opus Genetics' score of 0.23 indicating that Lifevantage is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifevantage 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AMRN or LFVN?

Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 20.13%. Given Lifevantage's higher possible upside, analysts clearly believe Lifevantage is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, AMRN or LFVN?

Lifevantage has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.33 -$38.80M -$0.65 N/A Lifevantage $228.53M 0.35 $9.81M $0.45 13.91

Is AMRN or LFVN more profitable?

Lifevantage has a net margin of 2.94% compared to Amarin's net margin of -15.51%. Lifevantage's return on equity of 23.89% beat Amarin's return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% Lifevantage 2.94% 23.89% 12.47%

Does the media favor AMRN or LFVN?

In the previous week, Amarin had 2 more articles in the media than Lifevantage. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.05 beat Amarin's score of -0.21 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lifevantage 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IKT or LFVN?

In the previous week, Inhibikase Therapeutics had 7 more articles in the media than Lifevantage. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.05 beat Inhibikase Therapeutics' score of 0.73 indicating that Lifevantage is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifevantage 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lifevantage (LFVN) Competitors

$6.26 +0.06 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$6.26 +0.00 (+0.08%)

As of 07:34 PM Eastern

Compare

LFVN vs. EDIT, IRD, AMRN, ELDN, and IKT

Should you buy Lifevantage stock or one of its competitors? MarketBeat compares Lifevantage with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifevantage include Editas Medicine (EDIT), Opus Genetics (IRD), Amarin (AMRN), Eledon Pharmaceuticals (ELDN), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

How does Lifevantage compare to Editas Medicine?

Lifevantage (NASDAQ:LFVN) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Lifevantage presently has a consensus target price of $5.00, indicating a potential downside of 20.13%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 87.50%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Lifevantage has a net margin of 2.94% compared to Editas Medicine's net margin of -281.59%. Lifevantage's return on equity of 23.89% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, Lifevantage and Lifevantage both had 1 articles in the media. Editas Medicine's average media sentiment score of 1.16 beat Lifevantage's score of 1.05 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifevantage has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.35	$9.81M	$0.45	13.91
Editas Medicine	$40.52M	6.96	-$160.06M	-$1.23	N/A

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 22.0% of Lifevantage shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lifevantage has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

Summary

Lifevantage beats Editas Medicine on 8 of the 15 factors compared between the two stocks.

How does Lifevantage compare to Opus Genetics?

Lifevantage (NASDAQ:LFVN) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Lifevantage presently has a consensus target price of $5.00, indicating a potential downside of 20.13%. Opus Genetics has a consensus target price of $10.77, indicating a potential upside of 253.09%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82

Lifevantage has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Opus Genetics had 2 more articles in the media than Lifevantage. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.05 beat Opus Genetics' score of 0.23 indicating that Lifevantage is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifevantage has a net margin of 2.94% compared to Opus Genetics' net margin of -892.36%. Lifevantage's return on equity of 23.89% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Opus Genetics	-892.36%	-338.88%	-191.21%

Lifevantage has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.35	$9.81M	$0.45	13.91
Opus Genetics	$14.20M	17.74	-$49.59M	-$1.33	N/A

Summary

Lifevantage beats Opus Genetics on 10 of the 16 factors compared between the two stocks.

How does Lifevantage compare to Amarin?

Amarin (NASDAQ:AMRN) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

22.3% of Amarin shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 22.0% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Amarin had 2 more articles in the media than Lifevantage. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.05 beat Amarin's score of -0.21 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifevantage	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifevantage has a consensus target price of $5.00, suggesting a potential downside of 20.13%. Given Lifevantage's higher possible upside, analysts clearly believe Lifevantage is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amarin has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Lifevantage has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.33	-$38.80M	-$0.65	N/A
Lifevantage	$228.53M	0.35	$9.81M	$0.45	13.91

Lifevantage has a net margin of 2.94% compared to Amarin's net margin of -15.51%. Lifevantage's return on equity of 23.89% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Lifevantage	2.94%	23.89%	12.47%

Summary

Lifevantage beats Amarin on 11 of the 16 factors compared between the two stocks.

How does Lifevantage compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Lifevantage had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for Eledon Pharmaceuticals. Lifevantage's average media sentiment score of 1.05 beat Eledon Pharmaceuticals' score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Neutral
Lifevantage	Positive

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 22.0% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lifevantage has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Lifevantage	$228.53M	0.35	$9.81M	$0.45	13.91

Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 150.43%. Lifevantage has a consensus price target of $5.00, suggesting a potential downside of 20.13%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lifevantage has a net margin of 2.94% compared to Eledon Pharmaceuticals' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Lifevantage	2.94%	23.89%	12.47%

Summary

Lifevantage beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Lifevantage compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Lifevantage (NASDAQ:LFVN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Inhibikase Therapeutics presently has a consensus target price of $5.40, indicating a potential upside of 142.15%. Lifevantage has a consensus target price of $5.00, indicating a potential downside of 20.13%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Inhibikase Therapeutics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Inhibikase Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

In the previous week, Inhibikase Therapeutics had 7 more articles in the media than Lifevantage. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 1 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.05 beat Inhibikase Therapeutics' score of 0.73 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifevantage	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifevantage has a net margin of 2.94% compared to Inhibikase Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Lifevantage	2.94%	23.89%	12.47%

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lifevantage has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,132.41	-$48.26M	-$0.43	N/A
Lifevantage	$228.53M	0.35	$9.81M	$0.45	13.91

Summary

Lifevantage beats Inhibikase Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Lifevantage News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFVN vs. The Competition

Export

Metric	Lifevantage	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$78.22M	$16.89B	$6.90B	$12.28B
Dividend Yield	3.23%	1.32%	2.67%	9.36%
P/E Ratio	13.91	19.25	22.26	21.51
Price / Sales	0.35	2.30	517.96	91.07
Price / Cash	5.64	14.30	26.68	47.25
Price / Book	2.28	3.27	10.66	6.14
Net Income	$9.81M	$534.24M	$3.60B	$331.74M
7 Day Performance	1.13%	-1.03%	-1.51%	-1.72%
1 Month Performance	-2.34%	5.23%	1.11%	-1.44%
1 Year Performance	-51.73%	3.48%	23.77%	16.97%

Lifevantage Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFVN Lifevantage	2.7127 of 5 stars	$6.26 +1.0%	$5.00 -20.1%	-52.2%	$78.22M	$228.53M	13.91	260	Positive News
EDIT Editas Medicine	2.8125 of 5 stars	$3.19 +0.8%	$5.40 +69.5%	+8.0%	$310.86M	$40.52M	N/A	230	Analyst Forecast Gap Down
IRD Opus Genetics	2.8543 of 5 stars	$3.76 -1.4%	$10.77 +186.8%	+189.4%	$309.47M	$14.20M	N/A	14
AMRN Amarin	1.4445 of 5 stars	$14.64 -0.4%	N/A	-11.9%	$307.09M	$213.65M	N/A	360	Analyst Forecast
ELDN Eledon Pharmaceuticals	1.3795 of 5 stars	$3.95 +2.2%	$9.67 +145.0%	+10.0%	$302.97M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFVN) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifevantage (LFVN) Competitors

LFVN vs. EDIT, IRD, AMRN, ELDN, and IKT

How does Lifevantage compare to Editas Medicine?

Summary

How does Lifevantage compare to Opus Genetics?

Summary

How does Lifevantage compare to Amarin?

Summary

How does Lifevantage compare to Eledon Pharmaceuticals?

Summary

How does Lifevantage compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifevantage (LFVN) Competitors

LFVN vs. EDIT, IRD, AMRN, ELDN, and IKT

How does Lifevantage compare to Editas Medicine?

Do analysts prefer LFVN or EDIT?

Is LFVN or EDIT more profitable?

Does the media prefer LFVN or EDIT?

Which has better valuation and earnings, LFVN or EDIT?

Do insiders and institutionals believe in LFVN or EDIT?

Which has more risk & volatility, LFVN or EDIT?

Summary

How does Lifevantage compare to Opus Genetics?

Do analysts prefer LFVN or IRD?

Which has more risk and volatility, LFVN or IRD?

Do insiders & institutionals believe in LFVN or IRD?

Does the media favor LFVN or IRD?

Is LFVN or IRD more profitable?

Which has preferable earnings & valuation, LFVN or IRD?

Summary

How does Lifevantage compare to Amarin?

Do insiders and institutionals hold more shares of AMRN or LFVN?

Does the media favor AMRN or LFVN?

Do analysts prefer AMRN or LFVN?

Which has more risk & volatility, AMRN or LFVN?

Which has better earnings and valuation, AMRN or LFVN?

Is AMRN or LFVN more profitable?

Summary

How does Lifevantage compare to Eledon Pharmaceuticals?

Does the media favor ELDN or LFVN?

Do institutionals & insiders have more ownership in ELDN or LFVN?

Which has preferable earnings & valuation, ELDN or LFVN?

Which has more volatility & risk, ELDN or LFVN?

Do analysts prefer ELDN or LFVN?

Is ELDN or LFVN more profitable?

Summary

How does Lifevantage compare to Inhibikase Therapeutics?

Do analysts prefer IKT or LFVN?

Which has more volatility and risk, IKT or LFVN?

Does the media prefer IKT or LFVN?

Is IKT or LFVN more profitable?

Do insiders & institutionals have more ownership in IKT or LFVN?

Which has higher earnings and valuation, IKT or LFVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFVN vs. The Competition

Lifevantage Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools